The role of tumor suppressor genes in esophageal cancer

Minerva Chirurgica

Volumn 57, Issue 6, 2002, Pages 767-780

  Raja, S ^a   Godfrey, T E ^a   Luketich, J D ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Cell cycle, regulation; Esophageal neoplasm; Tumor suppressor genes

Indexed keywords

APC; BISULFITE; CYCLIN D1; PROTEIN P16; PROTEIN P53;

CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DNA DETERMINATION; EARLY CANCER; EPIDEMIOLOGICAL DATA; EPITHELIUM; ESOPHAGUS CARCINOMA; GENE ACTIVATION; GENE DELETION; GENE INACTIVATION; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; MUTATION; NEOPLASM; PRECANCER; PROGNOSIS; REVIEW; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ESOPHAGEAL NEOPLASMS; FORECASTING; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; PROTO-ONCOGENES;

EID: 0036922794     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002;99:860-8.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
3. Yang CS. Research on esophageal cancer in China: a review. Cancer Res 1980;40:2633-44.
4. Yang PC, Davis S. Incidence of cancer of the esophagus in the US by histologic type. Cancer 1988;61:612-7.
5. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.
6. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
7. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
8. Kim R, Weissfeld JL, Reynolds JC, Kuller LH. Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 1997;6:369-77.
9. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-5.
10. Steup WH, De Leyn P, Deneffe G, Van Raemdonck D, Coosemans W, Lerut T. Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. J Thorac Cardiovasc Surg 1996;111:85-94.
11. Blom D, Peters JH, Demeester TR. Controversies in the current therapy of carcinoma of the esophagus. J Am Coll Surg 2002;195:241-50.
12. Silverberg E, Boring CC, Squires TS. Cancer statistics, 1990. CA Cancer J Clin 1990;40:9-26.
13. Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett's esophagus. N Engl J Med 1976;295:476-80.
14. Menke-Pluymers MB, Hop WC, Dees J, van Blankenstein M, Tilanus HW. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 1993;72:1155-8.
15. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
16. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985;313:857-9.
17. Incarbone R, Bonavina L, Saino G, Bona D, Peracchia A. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc 2002;16:263-6.
18. van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43:216-22.
19. Fernando HC, Luketich JD, Buenaventura PO, Perry Y. Christie NA. Outcomes of minimally invasive esophagectomy (MIE) for high-grade dysplasia of the esophagus. Eur J Cardiothorac Surg 2002;22:1-6.
20. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
21. Oncogenes and their proteins: classification and characteristics. In: Lodish H, Baltimore D, Berk A, Zipursky SL, Matsudaira P. Darnell J, editors. Molecular cell biology. 3rd ed. New York: Scientific American Books, Inc; 1995. p.1247-94.
22. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
23. Knudson AG Jr. Genetics of human cancer. Annu Rev Genet 1986;20:231-51.
24. Hu N, Huang J, Emmert-Buck MR, Tang ZZ, Roth MJ, Wang C et al. Frequent inactivation of the TP53 gene in esophageal squamous cell carcinoma from a highrisk population in China. Clin Cancer Res 2001;7:883-91.
25. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321:209-13.
26. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
27. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE et al. Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-30.
28. Tanaka H, Shimada Y, Harada H, Shinoda M, Hatooka S, Imamura M et al. Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res 1998;58:3429-34.
29. Oakeley EJ. DNA methylation analysis: a review of current methodologies. Pharmacol Ther 1999;84:389-400.
30. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92:1805-11.
31. Ginzinger DG, Godfrey TE, Nigro J, Moore DH, Suzuki S, Pallavicini MG et al. Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res 2000;60:5405-9.
32. Stocks SC, Pratt N, Sales M, Johnston DA, Thompson AM, Carey FA et al. Chromosomal imbalances in gastric and esophageal adenocarcinoma: specific comparative genomic hybridization-detected abnormalities segregate with junctional adenocarcinomas. Genes Chromosomes Cancer 2001;32:50-8.
33. Hu N, Roth MJ, Emmert-Buck MR, Tang ZZ, Polymeropolous M, Wang QH et al. Allelic loss in esophageal squamous cell carcinoma patients with and without family history of upper gastrointestinal tract cancer. Clin Cancer Res 1999;5:3476-82.
34. Roth MJ, Hu N, Emmert-Buck MR, Wang QH, Dawsey SM, Li G et al. Genetic progression and heterogeneity associated with the development of esophageal squamous cell carcinoma. Cancer Res 2001;61:4098-104.
35. Huang J, Hu N, Goldstein AM, Emmert-Buck MR, Tang ZZ, Roth MJ et al. High frequency allelic loss on chromosome 17p13.3-p11.1 in esophageal squamous cell carcinomas from a high incidence area in Northern China. Carcinogenesis 2000;21:2019-26.
36. Huang Y, Meltzer SJ, Yin J, Tong Y, Chang EH, Srivastava S et al. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res 1993;53:1889-94.
37. Ikeguchi M, Unate H, Maeta M, Kaibara N. Detection of loss of heterozygosity at microsatellite loci in esophageal squamous-cell carcinoma. Oncology 1999;56:164-8.
38. Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Ishida K, Saito K et al. Aberrations of tumor-suppressor genes (p53, apc, mcc and Rb) in esophageal squamous-cell carcinoma. Int J Cancer 1994;57:21-5.
39. Shimada Y, Imamura M, Shibagaki I, Tanaka H, Miyahara T, Kato M et al. Genetic alterations in patients withesophageal cancer with short- and long-term survival rodes after curative esophagectomy. Ann Surg 1997; 226:162-8.
40. Raja S, Finkelstein SD, Baksh FK, Gooding WE, Swalsky PA, Godfrey TE et al. Correlation between dysplasia and mutations of 6 tumor suppressor genes in Barrett's esophagus. Ann Thorac Surg 2001;72:1130-5.
41. Dunn J, Garde J, Dolan K, Gosney JR, Sutton R, Meltzer SJ et al. Multiple target sites of allelic imbalance on chromosome 17 in Barrett's oesophageal cancer. Oncogene 1999;18:987-93.
42. Wu TT, Watanabe T, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol 1998;153:287-94.
43. Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589-95.
44. Dolan K, Garde J, Walker SJ, Sutton R, Gosney J, Field JK. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus. Hum Pathol 1999;30:1508-14.
45. Gonzalez MV, Artimez ML, Rodrigo L, Lopez-Larrea C, Menendez MJ, Alvarez V et al. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol 1997;50:212-7.
46. Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Weber JL, Russell SE. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence. Gen Chrom Cancer 1998;21:49-60.
47. Dolan K, Garde J, Gosney J, Sissons M, Wright T, Kingsnorth AN et al. Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. Br J Cancer 1998;78:950-7.
48. Barrett MT, Galipeau PC, Sanchez CA, Emond MJ, Reid BJ. Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Oncogene 1996;12:1873-8.
49. Hammoud ZT, Kaleem Z, Cooper JD, Sundaresan RS, Patterson GA, Goodfellow PJ. Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. Cancer Res 1996;56:4499-502.
50. Blount PL, Meltzer SJ, Yin J, Huang Y, Krasna MJ, Reid BJ. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc Natl Acad Sci U S A 1993;90:3221-5.
51. Bian YS, Osterheld MC, Bosman FT, Benhattar J, Fontolliet C. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod Pathol 2001;14:397-403.
52. Romagnoli S, Roncalli M, Graziani D, Cassani B, Roz E, Bonavina L et al. Molecular alterations of Barrett's esophagus on microdissected endoscopic biopsies. Lab Invest 2001;81:241-7.
53. Mandard AM, Hainaut P, Hollstein M. Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res 2000;462:335-42.
54. Shi ST, Yang GY, Wang LD, Xue Z, Feng B, Ding W et al. Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions. Carcinogenesis 1999;20:591-7.
55. Muzeau F, Flejou JF, Thomas G, Hamelin R. Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers. Int J Cancer 1997;72:27-30.
56. Wong DJ, Barrett MT, Stoger R, Emond MJ, Reid BJ. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 1997;57:2619-22.
57. Klump B, Hsieh CJ, Holzmann K, Gregor M, Porschen R. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 1998;115:1381-6.
58. Xing EP, Nie Y, Wang LD, Yang GY, Yang CS. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. Carcinogenesis 1999;20:77-84.
59. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-34.
60. Boynton RF, Huang Y, Blount PL, Reid BJ, Raskind WH, Haggitt RC et al. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res 1991;51:5766-9.
61. Roncalli M, Bosari S, Marchetti A, Buttitta F, Bossi P, Graziani D et al. Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. Lab Invest 1998;78:1049-57.
62. Sarbia M, Tekin U, Zeriouh M, Donner A, Gabbert HE. Expression of the RB protein, allelic imbalance of the RB gene and amplification of the CDK4 gene in metaplasias, dysplasias and carcinomas in Barrett's oesophagus. Anticancer Res 2001;21:387-92.
63. Chen L, Matsubara N, Yoshino T, Nagasaka T, Hoshizima N, Shirakawa Y et al. Genetic alterations of candidate tumor suppressor ING1 in human esophageal squamous cell cancer. Cancer Res 2001;61:4345-9.
64. Li G, Hu N, Goldstein AM, Tang ZZ, Roth MJ, Wang QH et al. Allelic loss on chromosome bands 13q11-q13 in esophageal squamous cell carcinoma. Genes Chromosomes Cancer 2001;31:390-7.
65. Harada H, Tanaka H, Shimada Y, Shinoda M, Imamura M, Ishizaki K. Lymph node metastasis is associated with allelic loss on chromosome 13q12-13 in esophageal squamous cell carcinoma. Cancer Res 1999;59:3724-9.
66. Xing EP, Yang GY, Wang LD, Shi ST, Yang CS. Loss of heterozygosity of the Rb gene correlates with pRb protein expression and associates with p53 alteration in human esophageal cancer. Clin Cancer Res 1999;5:1231-40.
67. Hu N, Li G, Li WJ, Wang C, Goldstein AM, Tang ZZ et al. Infrequent mutation in the BRCA2 gene in esophageal squamous cell carcinoma. Clin Cancer Res 2002;8:1121-6.
68. Souza RF, Morales CP, Spechler SJ. Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus. Aliment Pharmacol Ther 2001;15:1087-100.
69. Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett's adenocarcinoma. Ann Surg 2001;233:322-37.
70. Gramlich TL, Fritsch CR, Maurer D, Eberle M, Gansler TS. Differential polymerase chain reaction assay of cyclin D1 gene amplification in esophageal carcinoma. Diagn Mol Pathol 1994;3:255-9.
71. Ogasawara S, Tamura G, Maesawa C, Suzuki Y, Ishida K, Satoh N et al. Common deleted region on the long arm of chromosome 5 in esophageal carcinoma. Gastroenterology 1996;110:52-7.
72. Choi YW, Heath EI, Heitmiller R, Forastiere AA, Wu TT. Mutations in β-catenin and APC genes are uncommon in esophageal and esophagogastric junction adenocarcinomas. Mod Pathol 2000;13:1055-9.
73. Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Weber JL, Russell SE. Allelotype analysis of adenocarcinoma of the gastric cardia. Br J Cancer 1997;76:1455-65.
74. Zhuang Z, Vortmeyer AO, Mark EJ, Odze R, Emmert-Buck MR, Merino MJ et al. Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. Cancer Res 1996;56:1961-4.
75. Rumpel CA, Powell SM, Moskaluk CA. Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol 1999;154:1329-34.
76. Peralta RC, Casson AG, Wang RN, Keshavjee S, Redston M, Bapat B. Distinct regions of frequent loss of heterozygosity of chromosome 5p and 5q in human esophageal cancer. Int J Cancer 1998;78:600-5.
77. Boynton RF, Blount PL, Yin J, Brown VL, Huang Y, Tong Y et al. Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci U S A 1992;89:3385-8.
78. Tarmin L, Yin J, Zhou X, Suzuki H, Jiang HY, Rhyu MG et al. Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. Cancer Res 1994;54:6094-6.
79. Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996;13:1867-73.
80. Kulke MH, Odze RD, Thakore KS, Thomas G, Wang H, Loda M et al. Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma. Br J Cancer 2001;84:748-53.
81. van Dekken H, Geelen E, Dinjens WN, Wijnhoven BP, Tilanus HW, Tanke HJ et al. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Res 1999;59:748-52.
82. Wijnhoven BP, de Both NJ, van Dekken H, Tilanus HW, Dinjens WN. E-cadherin gene mutations are rare in adenocarcinomas of the oesophagus. Br J Cancer 1999;80:1652-7.
83. Petty EM, Kalikin LM, Orringer MB, Beer DG. Distal chromosome 17q loss in Barrett's esophageal and gastric cardia adenocarcinomas: implications for tumorigenesis. Mol Carcinog 1998;22:222-8.
84. Nimura Y, Mihara M, Ichimiya S, Sakiyama S, Seki N, Ohira M et al. p73, a gene related to p53, is not mutated in esophageal carcinomas. Int J Cancer 1998;78:437-40.
85. Shimada M, Yanagisawa A, Kato Y, Inoue M, Shiozaki H, Monden M et al. Genetic mechanisms in esophageal carcinogenesis: frequent deletion of 3p and 17p in premalignant lesions. Gen Chrom Cancer 1996;15:165-9.
86. Hibi K, Taguchi M, Nakayama H, Takase T, Kasai Y, Ito K et al. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2001;7:3135-8.
87. Lam CT, Tang CM, Lau KW, Lung ML. Loss of heterozygosity on chromosome 11 in esophageal squamous cell carcinomas. Cancer Lett 2002;178:75-81.
88. Hu N, Huang J, Emmert-Buck MR, Tang ZZ, Roth MJ, Wang C et al. Frequent inactivation of the TP53 gene in esophageal squamous cell carcinoma from a high-risk population in China. Clin Cancer Res 2001;7:883-91.
89. Karkera JD, Ayache S, Ransome RJ jr, Jackson MA, Elsayem AF, Sridhar R et al. Refinement of regions with allelic loss on chromosome 18p11.2 and 18q12.2 in esophageal squamous cell carcinoma. Clin Cancer Res 2000;6:3565-9.
90. Pack SD, Karkera JD, Zhuang Z, Pak ED, Balan KV, Hwu P et al. Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations. Gen Chrom Cancer 1999;25:160-8.
91. Maesawa C, Tamura G, Ogasawara S, Suzuki Y, Sakata K, Sugimura J et al. Loss of heterozygosity at the DCC gene locus is not crucial for the acquisition of metastatic potential in oesophageal squamous cell carcinoma. Eur J Cancer 1996;32A:896-8.
92. Miyake S, Nagai K, Yoshino K, Oto M, Endo M, Yuasa Y. Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis. Cancer Res 1994;54:3007-10.
93. Ishii H, Dumon KR, Vecchione A, Trapasso F, Mimori K, Alder H et al. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 2001;61:1578-84.
94. von Brevern M, Hollstein MC, Risk JM, Garde J, Bennett WP, Harris CC et al. Loss of heterozygosity in sporadic oesophageal tumors in the tylosis oesophageal cancer (TOC) gene region of chromosome 17q. Oncogene 1998;17:2101-5.
95. Iwaya T, Maesawa C, Ogasawara S, Tamura G. Tylosis esophageal cancer locus on chromosome 17q25.1 is commonly deleted in sporadic human esophageal cancer. Gastroenterology 1998;114:1206-10.
96. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
97. Kubba AK, Poole NA, Watson A. Role of p53 assessment in management of Barrett's esophagus. Dig Dis Sci 1999;44:659-67.
98. Shimada H, Shimizu T, Ochiai T, Liu TL, Sashiyama H, Nakamura A et al. Preclinical study of adenoviral p53 gene therapy for esophageal cancer. Surg Today 2001;31:597-604.
99. Schrump DS, Chen GA, Consuli U, Jin X, Roth JA. Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4. Cancer Gene Ther 1996;3:357-64.
100. You L, Yang CT, Jablons DM. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 2000;60:1009-13.
101. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000;7:588-92.